SUBSCRIBERS

亚太生命科学领域蓬勃发展，新加坡吸引国际生物科技风投公司

特朗普的关税政策或促使企业重新评估投资，但该领域的长期前景预计不会改变

Add BT as a preferred source

Tessa Oh

Published Sun, Oct 5, 2025 · 06:29 PM — Updated Tue, Oct 7, 2025 · 08:11 AM

特朗普的药品关税对制药商的影响显而易见，但对研发创新药物的上游初创企业的影响则尚不明朗。照片：《商业时报》资料照片

DeeperDive is a beta AI feature. Refer to full articles for the facts.

本文由AI辅助翻译

查看原文

在本系列报道中，《商业时报》深入探讨了新加坡生物科技领域的现状，并探索一个关键挑战：如何将其世界一流的研发成果转化为商业成功。

系列首篇报道探讨了为何很少有本土公司在新加坡交易所上市的原因，本篇报道则将目光投向上游，随着国际生物科技风险投资公司纷纷涌入新加坡，我们发现了一幅更具活力的景象。后续报道将探讨该领域面临的宏观经济逆风以及行业的未来发展方向。

【新加坡】受亚太地区日益壮大的生命科学领域的吸引，国际生物科技风险投资（VC）公司正纷纷涌入新加坡，并且已确认又有一家欧洲风投公司将在年底前在此设立业务。

Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.

此翻译对您是否有帮助？

Venture capital Trump tariffs US tariffs Biotech Asia-Pacific

Reuse this content Feedback

TRENDING NOW

In this economy, the smartest bets might no longer be sitting an ocean away, but are waiting right here at home.

‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival

Sales have rebounded in March after the year-end lull and seasonal Chinese New Year pullback.

Near sell-out launches in March boost developer sales to 1,300 units after four slow months

US President Donald Trump (left) with Chinese President Xi Jinping at a bilateral meeting on the sidelines of the Apec summit in Busan last October.

China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result

Lim's pay package includes about S$3.6 million as salary and around S$3.9 million as bonus, indicates the company's annual report.

Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025